~~<i id='8593A4F73C'><strike id='8593A4F73C'><tt id='8593A4F73C'><pre id='8593A4F73C'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

fashion

author：entertainment 2025-10-03 00:06:37 - browse：2913

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Wikipedia

focus

hotspot

entertainment

explore

focus

1:54LeslieVanHoutenattendsherparolehearingattheCaliforniaInstitutionforWomenSept.6,2017inCorona,Cali

WSS

New research casts further doubt on a common procedure used with IVF

ACIP vaccine advisory panel sees its vacancies filled

DOJ reversal could clear way for Carroll's 1st lawsuit against Trump to proceed

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Resistance to opioid

knowledge

fashion

Wikipedia

DIEP, the 'gold standard' of breast reconstruction, is under threat

Bernie Sanders gets little from pharma CEOs on drug prices

Peter Hotez and the public health issue of online harassment

Elizabeth Holmes on track for early release from her 11

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Tome Biosciences co

In Memoriam: Notable people who died in 2023

Resistance to opioid

Guidelines to prevent youth baseball injuries need more muscle

Charles Manson follower Leslie Van Houten released from prison after 53 years

focus

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Too many hospitalized Covid

Websites selling Wegovy, Zepbound ingredients targeted by FDA

New research casts further doubt on a common procedure used with IVF

It's time to get medical device identifiers over the finish line

Threats against the LGBTQIA+ community intensifying: Department of Homeland Security

hotspot

entertainment

explore

focus